Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-Stat Flowable Hemostat is a combination biologic-device hemostatic agent originally developed by Vascular Solutions and now owned by Teleflex. It is composed of bovine-derived thrombin (5,000 units) and bovine collagen (200mg), which are mixed with a buffered diluent containing calcium chloride and tromethamine to create a flowable suspension. The product is indicated for the control of bleeding from vascular access sites and percutaneous catheters, as well as for sealing tissue tracts and reducing clinically relevant hematoma formation in high-risk anticoagulated patients undergoing pulse generator (pacemaker or ICD) implantation. Its mechanism of action is dual-pronged: the thrombin component enzymatically converts fibrinogen into fibrin to initiate clot formation, while the collagen component promotes platelet aggregation and provides a structural matrix to facilitate hemostasis. It is biocompatible, non-pyrogenic, and intended to be left in situ after application.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-Stat Flowable Hemostat.